相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis
A. N. Nafziger et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis - Respose to Nafziger and Bertino
Y. Kaneshiro et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers
Emmanuel Krupka et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam
HN Chaobal et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity
CB Eap et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Single plasma concentrations of 1′-hydroxymidazolam or the ratio of 1′-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects
JF Rogers et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: Application to various assay techniques
JS Kim et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration
YS Lin et al.
PHARMACOGENETICS (2001)
Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes
DS Streetman et al.
PHARMACOGENETICS (2000)
分享论文
